Cadrenal Therapeutics (CVKD) Shares Outstanding (2022 - 2026)

Cadrenal Therapeutics has reported Shares Outstanding (Entity) for 5 years, with the latest figure at $2.5 million in Q1 2026.

• Quarterly Shares Outstanding (Entity) rose 31.27% year-over-year to $2.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.5 million (up 31.27% YoY) and the FY2025 annual result came in at $2.3 million, up 91.72% from the prior year.
• Shares Outstanding (Entity) climbed to $2.5 million in Q1 2026 per CVKD's latest filing, from $2.3 million in the prior quarter.
• Over five years, Shares Outstanding (Entity) peaked at $2.5 million in Q1 2026 and troughed at $91771.0 in Q4 2022.
• A 5-year average of $1.2 million and a median of $1.1 million in 2024 frame the typical range for Shares Outstanding (Entity).
• The sharpest annual moves came in 2023 and 2026: Shares Outstanding (Entity) surged 846.08% in 2023, then soared 31.27% in 2026.
• Over 5 years, Shares Outstanding (Entity) stood at $91771.0 in 2022, then soared by 846.08% to $868227.0 in 2023, then soared by 40.46% to $1.2 million in 2024, then jumped by 91.72% to $2.3 million in 2025, then increased by 7.21% to $2.5 million in 2026.
• According to Business Quant data, Shares Outstanding (Entity) over the past three periods registered $2.5 million, $2.3 million, and $2.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.